There are also other trials that continue to evaluate BTK inhibitors in combination with other drugs for DLBCL (such as ibrutinib (NCT02077166), acalabrutinib (NCT04546620), and zanubrutinib (NCT04436107)). The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.